Halberd Corp. Develops Second Covid-19 Antibody for Enhanced Nasal Spray and Doubles Performance of New Class of Antibody
Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a key functional parameter. Dr. Mitchell S. Felder, a Halberd consultant, filed a provisional patent application for a nasal spray utilizing ...
Halberd Corp. CEO Interviewed on Money TV
In Case You Missed It - Mr. Hartman discusses recent accomplishments and new opportunities. Jackson Center, PA, November 2, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided an update on the company’s latest activities, and new efforts underway. Mr. Baillargeon began the interview by asking how Halberd decided on its university research partner. Mr. ...
Halberd Corp. Development Efforts Transcend Covid-19 Prevention, Diagnostics & Therapeutics
Jackson Center, PA, October 29, 2020 – Halberd Corporation (OTC PINK: "HALB") today provided insight concerning its strategic plans beyond developing unique antibodies which form the basis of their current all-out efforts to generate products and processes to prevent, diagnose and treat Covid-19. These strategic plans are designed to benefit people well after Covid-19 is no longer an issue. William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “Currently, we are dedicating our maximum ...
Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies
Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney on the Halberd account is Dr. Darwin King, Esq., who has extensive experience in dealing with intellectual property matters in ...
ICYMI — Halberd Corporation Discusses The Development of New Class of COVID-19 Antibody with The Stock Day Podcast
In Case You Missed It Phoenix, Arizona–(Newsfile Corp. – October 22, 2020) – The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly. Jolly began the interview by asking about Hartman’s transition from his former position as the CEO of Premier Biomedical to ...
Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody
Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. Felder, MD. Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for ...